rituximab specifically recognizes and attaches to a protein called cd20 that is found on the surface of some lymphocytes.

1、

conclusion: rituximab can bind to b cells which express cd20 antigen and induce b cell apoptosis by antigen-antibody reaction.

结论：抗CD20抗体能靶向性地与表达CD20抗原的B细胞结合，通过抗体抗原反应，诱导B细胞加速凋亡。

互联网摘选

2、

successful treatment of musk antibody-positive myasthenia gravis with rituximab

利妥昔单抗成功治疗MuSK抗体阳性重症肌无力患者

互联网摘选

3、

comparison of rituximab plus chop regimen and chop regimen alone for treatment of patients with aggressive b-cell lymphoma

美罗华联合CHOP方案与CHOP方案治疗侵袭性B细胞性淋巴瘤的临床对比研究

互联网摘选

4、

the observation of clinical efficacy of rituximab in combination with dhap chemotherapy in patients with relapsed non-hodgkin lymphoma

利妥昔单抗联合DHAP方案治疗复发性非霍奇金淋巴瘤的临床疗效

互联网摘选

5、

it is possible to achieve selective depletion of b lymphocytes with rituximab, an anti-cd20 monoclonal antibody.

用抗CD20的单克隆抗体利妥昔单抗能够做到选择性的消耗B淋巴细胞。

互联网摘选

6、

objective to investigate the efficacy and safety of combined fludarabine and rituximab therapy for chronic lymphocytic leukemia in old patients.

目的考察氟达拉滨联合治疗高龄慢性淋巴细胞白血病患者的有效性和安全性。

互联网摘选

7、

objective to study the biological response of b-cell lymphoma cells positive for cd20 expression to 131i-labeled rituximab.

目的研究131I标记的rituximab对CD20高表达的B细胞淋巴瘤细胞的生物学效应，为放射免疫导向治疗提供实验依据。

互联网摘选

8、

a meta-analysis on rituximab combined chemotherapy for non-hodgkin lymphoma

美罗华联合化疗对非霍奇金淋巴瘤疗效的Meta分析

互联网摘选

9、

this is the first study demonstrating a clear benefit of rituximab maintenance following a rituximab-containing induction regimen.

这是首个显示出在进行了包含美罗华的诱导疗法之后采用美罗华维持疗法有明显益处的试验。

互联网摘选

10、

rituximab: a monoclonal antibody to cd20 used in the treatment of pemphigus vulgaris

利妥昔单抗：一种用于治疗寻常型天疱疮的抗CD20单克隆抗体

互联网摘选

11、

there was no increase in infections or neutropenia with rituximab.

感染和中性粒细胞减少症都没有增加。

互联网摘选

12、

an uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes

一项利妥昔单抗治疗副肿瘤性神经系统综合征相关抗体的非对照试验

互联网摘选

13、

we examined the significance of bone marrow involvement in patients treated in the current era of therapy including rituximab.

我们的研究旨在探讨骨髓侵犯对接受利妥昔单抗联合化疗的受试者的预后影响。

互联网摘选

14、

chop chemotherapy plus rituximab for elderly patients with diffuse large-b-cell lymphoma

CHOP方案联合利妥昔单抗治疗弥漫大B细胞淋巴瘤

互联网摘选

15、

conclusion rituximab combined with chemotherapy is a highly effective and well-tolerated treatment in b cell nhl.

结论美罗华联合其它化疗药物治疗B细胞淋巴瘤疗效好，患者耐受好。

互联网摘选

16、

the clinical study of chop combined with rituximab in treating b-cell non-hodgkin lymphoma

美罗华联合CHOP治疗B细胞性非霍奇金淋巴瘤的临床研究

互联网摘选

17、

the therapeutic effects of rituximab on 32 diffuse large b cell non-hodgkin lymphoma cases

美罗华治疗32例弥漫型大B细胞性非何杰金氏淋巴瘤

互联网摘选

18、

the rituximab group also had significantly lower levels of glycated hemoglobin and required less insulin.

另外，相对于安慰机组，利妥昔单抗组的糖化血红蛋白和胰岛素必须量都明显较低。

互联网摘选

19、

treatment of b-cell lymphoma with the regimen of rituximab combined chemotherapy

利妥昔单抗联合化疗方案治疗B细胞淋巴瘤

互联网摘选

20、

efficacy of rituximab in patients with refractory severe systemic lupus erythematosus

利妥昔单抗治疗难治性重症系统性红斑狼疮的临床初步观察

互联网摘选